Iterum Therapeutics Plc (ITRM): Next-Year EPS Estimate 316.67%
As of 2026-04-01, Iterum Therapeutics Plc (ITRM) has a next-year EPS growth estimate of 316.67%.
On 2026-04-01, analyst consensus for ITRM's next-year EPS growth shifted from 53.03% to 316.67% — a positive change of 263.64 percentage points.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 316.67%
- EPS growth this year
- N/A
- EPS next quarter (est)
- N/A
- Last price
- $0.03
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-04-01 | 316.67% | N/A | N/A | $0.03 |
| 2026-03-31 | 53.03% | N/A | N/A | $0.03 |
| 2026-03-31 | 53.03% | N/A | N/A | $0.03 |
| 2026-03-31 | 53.03% | N/A | N/A | $0.03 |
| 2026-03-30 | 53.03% | N/A | N/A | $0.07 |
| 2026-03-30 | 67.12% | N/A | N/A | $0.07 |
| 2026-03-30 | 67.12% | N/A | N/A | $0.07 |
| 2026-03-29 | 53.03% | N/A | N/A | $0.04 |
| 2026-03-29 | 53.03% | N/A | N/A | $0.04 |
| 2026-03-27 | 53.03% | N/A | N/A | $0.04 |
| 2026-03-26 | 53.03% | N/A | N/A | $0.18 |
| 2026-03-26 | 53.03% | N/A | N/A | $0.18 |
| 2026-03-26 | 53.03% | N/A | N/A | $0.18 |
| 2026-03-25 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-25 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-25 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-24 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-24 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-24 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-23 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-20 | 53.03% | N/A | N/A | $0.16 |
| 2026-03-19 | 53.03% | N/A | N/A | $0.17 |
| 2026-03-18 | 53.03% | N/A | N/A | $0.18 |
| 2026-03-17 | 53.03% | N/A | N/A | $0.17 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Iterum Therapeutics Plc's next-year EPS growth estimate?▾
As of 2026-04-01, Iterum Therapeutics Plc (ITRM) has a next-year EPS growth estimate of 316.67%, based on analyst consensus.
When was the latest EPS estimate revision for ITRM?▾
The most recent revision occurred on 2026-04-01, when analysts adjusted the next-year EPS growth estimate from 53.03% to 316.67%.
What sector and industry does Iterum Therapeutics Plc belong to?▾
Iterum Therapeutics Plc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ITRM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Iterum Therapeutics Plc (ITRM) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports